Healthy volunteers help uncover drug interactions for new compound
NCT ID NCT07018635
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed phase 1 study looked at how three common drugs—an antifungal (itraconazole), an antibiotic (rifampin), and acid reducers (esomeprazole, famotidine)—change the way a new experimental drug (INCB161734) moves through the body. Sixty-three healthy adults aged 18 to 55 took part. The goal was purely to gather safety and drug-level data, not to treat any disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
INCB161734
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fortrea Clinical Research Unit Ltd Labcorp Clinical Research Unit Limited Madison
Madison, Wisconsin, 53704, United States